On October 22, 2024, Novo Nordisk submitted a nomination to the FDA, arguing that semaglutide products belong on the Demonstrable Difficulties for Compounding (DDC) list due to the complexities associated with their formulations, delivery mechanisms, dosage forms, achievement of bioavailability, compounding processes, and physicochemical and analytical testing. The FDA has yet to make a final decision on whether to ban compounded versions of semaglutide
ROS production was expressed as luminescence intensity, and the percentage of control cells (CTR, SG condition) was reported
Patient descriptions from TRIUMPH-4: "Tingling in my hands and feet, like they fell asleep" "Strange sensation when I touch my skin, not painful but unusual" "Numbness in fingertips, comes and goes" "Pins and needles feeling, especially in the morning" NOT described: Severe pain Progressive worsening (stays stable or improves) Interference with daily activities (most continued trial) Why Is This Unique to Retatrutide
n , Total number of complete wheel turns ( n = 10 fed, n = 6 LiCl, n = 9 Lira, n = 9 Dan, n = 8 Orfo)
Endocrine 29 (2), 209215
